Pathology: Grade 1 infiltrating ductal carcinoma with associated DCIS, Lymphvascular invasion present. ER+, PR+. Her 2/ IHC 1+, negative

Similar documents
Case Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.

Case Scenario 1 History and Physical 3/15/13 Imaging Pathology

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.

Standards for Cancer Registries, Volume II: Data Standards and Data Dictionary, Eighth Edition. COC Collect. COC Transmit

Q&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast

1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ Primary Site (291) = C711 Date of Diagnosis (283) =

1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ 2 Primary Site (291) = C711 Date of Diagnosis (283) =

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

ASCR Data Items for V14 ASCR Requirement: R - Required Fields, S - Supplemental Fields, * - When available CR Only - only need for Central Registry

APPENDIX D: ASCR REQUIRED DATA ELEMENTS (Version 13)

Interactive Discussion of Part I CS Coding Instructions: Working the Cases

Collecting Cancer Data: Breast. Prizes! Collecting Cancer Data: Breast 8/4/ NAACCR Webinar Series 1. NAACCR Webinar Series

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

Breast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined

Breast Cancer. Saima Saeed MD

What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine

Q: How do you clinically code the N if the nodes are stated to be positive on mammogram/us or other imaging? No biopsy of nodes was done.

Case Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.

ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:

Completing the Puzzle AJCC TNM Staging Breast. Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017

Case Scenario 1: Thyroid

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

Pancreas Case Scenario #1

1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

Surgical Therapy: Sentinel Node Biopsy and Breast Conservation

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue

Educational Goals and Objectives for Rotations on: Breast, Wound and Plastic Surgery

Pathology Report Patient Companion Guide

ACRIN 6666 Therapeutic Surgery Form

Ductal Carcinoma-in-Situ: New Concepts and Controversies

Breast Health. Program Objectives. Facts About Breast Cancer in the United States

Case Scenario 1. Pathology: Specimen type: Incisional biopsy of the glottis Histology: Moderately differentiated squamous cell carcinoma

Informational Abstracts: A Guide to Quality Abstracting

Breast Cancer Diagnosis, Treatment and Follow-up

ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *

How can surgeons help the Radiation Oncologists?

Advances in Localized Breast Cancer

Breast Cancer. Dr. Andres Wiernik 2017

University Clinical Center Banja Luka, Breast Center - Banja Luka, Bosnia and Herzegovina

Breast Imaging: Multidisciplinary Approach. Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina

CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I

Presented by: Lillian Erdahl, MD

Case Scenario #1 Larynx

Conservative Surgery and Radiation Stage I and II Breast Cancer

Melanoma Case Scenario 1

FINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma

Case study 1. Rie Horii, M.D., Ph.D. Division of Pathology Cancer Institute Hospital, Japanese Foundation for Cancer Research

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Barlavento Medical Centre - Portimão, Portugal

HOSPITAL MODELO - LA CORUÑA, Spain

Handout for Dr Allison s Lectures on Grossing Breast Specimens:

Melanoma Case Scenario 1

How to Use MRI Following Neoadjuvant Chemotherapy (NAC) in Locally Advanced Breast Cancer

Advances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015

STAGE CATEGORY DEFINITIONS

Case Scenario 1: Breast

Exercise. Discharge Summary

EVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013

Surgery for Breast Cancer

Lung. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded.

Mamma Centrum / Zelený Pruh - Prague, Czech Republic

Barriers to Understanding

FCDS 2013 EDUCATION WEBCAST SERIES: BREAST CANCER

Case Scenario 1. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

11/21/13 CEA: 1.7 WNL

Breast. Presentation Outline

Breast. FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.

Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.

Seventh Edition Staging 2017 Breast

Case Scenario. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

Dyson Center for Cancer Care - Poughkeepsie, New York, United States of America

AMSER Case of the Month: September 2018

Collaborative Stage Site-Specific Instructions - BREAST

National Center of Oncology - Yerevan, Armenia

Prostate Case Scenario 1

Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Pathology. AGO e. V. in der DGGG e.v. sowie in der DKG e.v.

Breast Unit - University of Heidelberg - Heidelberg, Germany

San Donato Hospital - Azienda USL TOSCANA SUDEST Arezzo - Arezzo, Italy

Hospital Universitari La Fe - Valencia, Spain

Breast Cancer FAQ. How does Breast Cancer spread? Breast cancer spreads by invading into

Surgical Advances in the Treatment of Breast Cancer. Laura Kruper, MD, MSCE Chief, Breast Surgery

Guven Hospital - Ankara, Turkey

Breast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?

Breast Cancer Task Force of the Greater Miami Valley A collaborative effort of health care professionals and breast cancer survivors in the Greater

2010 Cancer Data Collection Updates: Standards Volume II, Introduction. What s New for 2010

Breast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015

Alternate Name Item # Length Source of Standard Column # Alternate Name Item # Length Source of Standard Column #

Ippocration Hospital University of Athens - Athens, Greece

Breast cancer incidence. Multidisciplinary Management in Breast Cancer. Outline. The Breast 11/10/2014. Incidence of breast cancer in Thailand

Requirements for Abstracted Text

Clinica Medellin - Medellin, Colombia

Cork University Hospital - Cork, Ireland

Civic Hospital of Sanremo ASL 1 Imperiese - Sanremo, Italy

A712(18)- Test slide, Breast cancer tissues with corresponding normal tissues

Jessa Hospital - Hasselt, Belgium

PLACE LABEL HERE. ACRIN 6657 MRI Form: Pre-Treatment (MRI-1)

Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ]

Invasive Papillary Breast Carcinoma

Transcription:

GATRA 2016 Breast Case Demographics Name: Autumn Leaf Sex: F Date of Birth: 3/26/75 SSN: 098765432 Race: African American Marital Status: Single Address: 3615 Burnt Hickory Trail, Helen, GA 37285, White County Phone: 123 456 7890 Insurance: AETNA PPO 2/11/15 @ Reporting Hospital 39 year old single black female presents for MMG/Ultrasound of selfpalpated mass in right breast. Physical exam demonstrates a palpable mass in the upper outer quadrant of the right breast with no visible skin changes. No palpable lymphadenopathy. 2/11/15 @ Reporting Hospital MMG/US Patient has palpable lump right breast MMG calcifications upper outer quadrant right breast, left breast wnl. Ultrasound multiple solid masses right breast 10:00, 7 cm from nipple. Largest 1.4 cm, second mass 1.2 cm. Mildly prominent lymph node in right axilla. 2/25/15 @ Reporting Hospital/Dr XXXX right breast stereotactic core bx Pathology: Grade 1 infiltrating ductal carcinoma with associated DCIS, Lymphvascular invasion present. ER+, PR+. Her 2/ IHC 1+, negative 3/16/15 @ Reporting Hospital Breast MRI clumped non mass enhancement lateral right breast extending into low axillary tail/posterior lateral chest wall, total extent of disease measures approximately 6 cm. Areas of enhancement on right pectoralis muscle suspicious for muscle invasion. Prominent right axillary lymph node. 1.4 cm lesion hepatic dome. 4/13/15 @ Reporting Hospital PET/CT negative for mets; hypodensity in liver likely benign. 4/25/15 @ Dr XXXX Ms. Leaf presents for consultation status post right breast biopsy positive for infiltrating ductal carcinoma with imaging suspicious for regional lymph node involvement. Due to multifocal disease a mastectomy is recommended. Ms. Leaf will follow with Dr. YYYY for reconstruction options. Surgery will be scheduled for next month. 5/20/15 @ Reporting Hospital/Dr XXXX/Dr YYYY Right nipple sparing mastectomy/sln bx/reconstruction w/ tissue expander Dye injected, breast removed; at uoq right breast, it appears to include some axillary contents as there were multiple palpable areas in this area; however, there was no blue dye identified. No blue dye identified in the right axilla, though the level 1 & 2 regions were evaluated, no nodes were

seen & none dyed blue. There was a nodular area in level1 that was excised suspected to be a lymph node. Pathology: Right sentinel lymph node frozen section: positive for infiltrating ductal carcinoma, not certain it represents lymph node tissue. Gross description: 3 possible lymph nodes. Final dx for sentinel lymph node specimen: Infiltrating ductal carcinoma in breast tissue w/ associated dcis. No lymphoid tissue identified. Right breast specimen: 4.6 cm infiltrating ductal carcinoma, Nottingham score 5. DCIS present, multiple foci of invasive carcinoma. No skin or muscle invasion. No lymphvascular invasion. Margins negative. 6/30/15 9/15/15 @ Outside Medical Oncologist Taxotere, Cytoxan x 4 10/6/15 11/23/15 @ Reporting Hospital/Dr ZZZZ Right breast/right axilla 6/18 mv photons 50.4 Gy/28 fx + 6 mv photon boost 14 Gy/7 fxs. Total 64.4 Gy/35 fxs 12/1/15 @ Outside Medical Oncologist Tamoxifen

FIELD# FIELD NAME CODE AND RATIONALE/DOCUMENTATION Last Name First Name Address at DX-No and Street Address at DX-City Address at DX-State Address at DX-Postal Code County at DX Telephone Primary Payer at DX Sex Date of Birth Age at Diagnosis Birthplace Social Security Number Marital Status at DX Race 1 Race 2 Race 3 Race 4 Race 5 Spanish Surname or Origin CANCER IDENTIFICATION Date of 1 st Contact Sequence Number Class of Case Date of Diagnosis Primary Site Laterality Histology: Behavior Grade Lymph-vascular invasion Diagnostic Confirmation COLLABORATIVE STAGE CS Tumor Size CS Extension CS Tumor Size/Ext Eval CS Lymph Nodes CS Lymph Nodes Eval Regional Nodes Positive Regional Nodes Examined CS Mets at Dx CS Mets Eval CS Mets at Dx -- Bone CS Mets at Dx Lung CS Mets at Dx Liver CS Mets at DX Brain SSF1 Estrogen Receptor Assay SSF2 Progesterone Receptor Assay SSF3 # Pos Ipsi Level I-II Axill

LNs SSF4 IHC of Reg LNs SSF5 MOL Studies of Reg LNs SSF6 Size of Tumor Invasive Component SSF7 Nottingham (BR) Score SSF8 HER2 IHC Lab Value SSF9 HER2 IHC Test Interpretation SSF10 HER2 FISH Lab Value SSF 11 HER2 FISH Interpretation SSF 12 HER2 CISH Lab Value SSF 13 H2 CISH Interpretation SSF 14 HER2 Other/Unk Test Result SSF 15 HER2 Summary Result Test SSF 16 Combination ER, PR, HER2 SSF 21 Respone to Neoadjuvant TX SSF 22 Multigene Signature Method SSF 23 Multigene Signature Results Clinical TNM Pathologic TNM Derived TNM Summary Stage TREATMENT FIRST COURSE Date of Initial RX SEER Date of 1 st Crs RX COC RX Hosp Surg Prim Site RX Hosp Scope RegLN Sur RX Hosp Surg Oth Reg/Dis RX Hosp Chemo RX Hosp Hormone RX Hosp BRM RX Hosp-Transplnt/Endo RX Hosp Other Reason for No Surgery RX Date Surgery RX Summ Surg Prim Site RX Summ Scope Reg LN RX Summ Surg Oth Reg/Dist Site RX Summ Radiation Reason for No Radiation Rad Regional RX Modality Rad Boost RX Modality RX Date Radiation RX Summ Surg/Rad Seq RX Date Chemo

RX Summ Chemo RX Date Hormone RX Summ Hormone RX Date BRM RX Summ BRM RX Summ-Transplnt/Endo RX Date Systemic RX Summ Sys/Sur Seq RX Summ Other RX Date -- Other RX Summ Treatment Status